On September 9th, the United States Court of Appeals for the District of Columbia denied a motion to stay filed by SAM, Inc. and the National Drug and Alcohol Screening Association, Inc. (collectively, “SAM”). The motion sought to stay (pause) the Attorney General’s final order placing state legal medical marijuana into Schedule III of the
Colorado regulates marijuana businesses through the state Marijuana Enforcement Division (MED), while local jurisdictions retain separate licensing and regulatory authority over marijuana businesses within their boundaries. The current Colorado Marijuana Rules are codified at 1 CCR 212-3 (version effective January 5, 2026). Because state rules, forms, fee schedules, and local ordinances can change, applicants should
Earlier this week, the House passed a short-term funding bill that postpones the federal ban on hemp-derived THC products. President Trump signed the ban into law last year; it was scheduled to take effect November 12th. This Wednesday, however, Trump signed off on the Congressional extension, pushed by his Administration, which means the ban is
With so much of my attention focused on U.S. rescheduling lately, I wanted to take advantage of the D.C. Circuit’s delay and the DEA ALJ’s delayed timeline. This gives me an opportunity to get back into some considerations on international cannabis reform. Who controls government is one of the most important factors when discussing cannabis
It’s been a while since we wrote a round-up post on Oregon cannabis. Here are some items of note, as we head into the fall. Gather ‘round! Proposed THC cap and packaging requirements On August 19th, the Oregon Capital Chronicle ran an article featuring a renewed push by Sen. Lisa Reynolds (D-Portland) to cap individual
Five bills moving through the California legislature right now could reshape how DCC investigates violations, what gets tested and disclosed at retail, and what cannabis packaging can even look like. This post breaks down AB 1826, AB 1965, AB 2249, AB 2532, and AB 2537 in plain terms, explains how they interlock, and offers a practical compliance checklist for operators who want to get ahead of these changes before final enactment.
Rescheduling has reshaped the legal landscape for California Cannabis businesses, but many existing contracts haven't caught up. This post breaks down where supply, licensing, and investment agreements now fall short—covering gaps in DEA registration language, license conversion triggers, and 280E-related representations—and offers a practical framework for reviewing and updating agreements before those gaps become disputes.
Federal rescheduling turned California cannabis license designations into real strategy decisions, not just paperwork. This post explains when and how to convert or split A/M licenses, why medical vs adult-use separation now matters for 280E and DEA planning, and why every link in the supply chain needs its own clearly defined medical channel.
Cannabis law has never been more contradictory. In the U.S., federal and state governments often regulate identical products under completely different legal frameworks. Hemp and marijuana can produce the same intoxicating effects, yet lawmakers treat them as fundamentally different. Medical marijuana now occupies a unique place under federal law while adult use marijuana remains prohibited.
Federal rescheduling has finally arrived, but it didn’t magically solve everything for California cannabis businesses. Instead, it created a new set of decisions: whether to pursue DEA registration as a medical operator, how and when to restructure DCC licenses, and what 280E relief actually looks like for mixed medical/adult use companies. This article walks through the concrete steps California operators should take now — including what to do if you missed the initial DEA registration window.
